Identifcaiton of cancer stem cells in HNSCC
| Project/Area Number |
18K09334
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56050:Otorhinolaryngology-related
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
Morita Shinkichi 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (10773955)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
玉井 恵一 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 部長 (40509262)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 下咽頭癌 / PDX / 頭頸部癌 |
|---|
| Outline of Final Research Achievements |
This study aims to test whether CD271, which is a stem cell marker in hypopharyngeal cancer, is a good target in therapy. A humanized anti-CD271 antibody was developed. The antibody possessed antibody-dependent cellular cytotoxicity capacity against cancer cells in vitro. Antibody administration in mice bearing human cancer cells led to tumor volume suppression. CD271-positive cancer cells in the antibody-treated mice decreased. Collectively, the CD271 antibody treatment for hypopharyngeal cancer is a promising therapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では抗CD271抗体が癌の治療に使えることをマウスモデルを用いて示した。今後更に検討を重ね、臨床応用の検討を進める。
|
Report
(5 results)
Research Products
(1 results)
